Lyra Therapeutics Files 8-K
Ticker: LYRA · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, regulation-fd
TL;DR
Lyra Therapeutics filed an 8-K on Jan 10, 2025, mostly for financial docs & Reg FD.
AI Summary
Lyra Therapeutics, Inc. filed an 8-K on January 10, 2025, to report current information. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure. No specific material events or financial figures beyond the filing date are detailed in this initial report.
Why It Matters
This 8-K filing indicates Lyra Therapeutics is providing updated information to the SEC, which could include material disclosures relevant to investors.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for financial statements and exhibits, not indicating any immediate negative or positive material events.
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- January 10, 2025 (date) — Date of Report
- 001-39273 (other) — Commission File Number
- 480 Arsenal Way, Watertown, Massachusetts 02472 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Lyra Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report current information, specifically concerning financial statements and exhibits, and a Regulation FD Disclosure.
On what date was this 8-K report filed?
This 8-K report was filed on January 10, 2025.
What is Lyra Therapeutics, Inc.'s state of incorporation?
Lyra Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Lyra Therapeutics, Inc.?
The Commission File Number for Lyra Therapeutics, Inc. is 001-39273.
Where are Lyra Therapeutics, Inc.'s principal executive offices located?
Lyra Therapeutics, Inc.'s principal executive offices are located at 480 Arsenal Way, Watertown, Massachusetts 02472.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-01-10 16:02:03
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share LYRA The Nasdaq
Filing Documents
- d905375d8k.htm (8-K) — 24KB
- d905375dex991.htm (EX-99.1) — 27KB
- g905375ex99_1s10g1.jpg (GRAPHIC) — 63KB
- g905375ex99_1s11g1.jpg (GRAPHIC) — 66KB
- g905375ex99_1s12g1.jpg (GRAPHIC) — 64KB
- g905375ex99_1s13g1.jpg (GRAPHIC) — 108KB
- g905375ex99_1s14g1.jpg (GRAPHIC) — 84KB
- g905375ex99_1s15g1.jpg (GRAPHIC) — 77KB
- g905375ex99_1s16g1.jpg (GRAPHIC) — 71KB
- g905375ex99_1s17g1.jpg (GRAPHIC) — 104KB
- g905375ex99_1s18g1.jpg (GRAPHIC) — 104KB
- g905375ex99_1s19g1.jpg (GRAPHIC) — 74KB
- g905375ex99_1s1g1.jpg (GRAPHIC) — 56KB
- g905375ex99_1s20g1.jpg (GRAPHIC) — 44KB
- g905375ex99_1s21g1.jpg (GRAPHIC) — 36KB
- g905375ex99_1s22g1.jpg (GRAPHIC) — 50KB
- g905375ex99_1s2g1.jpg (GRAPHIC) — 210KB
- g905375ex99_1s3g1.jpg (GRAPHIC) — 97KB
- g905375ex99_1s4g1.jpg (GRAPHIC) — 89KB
- g905375ex99_1s5g1.jpg (GRAPHIC) — 77KB
- g905375ex99_1s6g1.jpg (GRAPHIC) — 93KB
- g905375ex99_1s7g1.jpg (GRAPHIC) — 73KB
- g905375ex99_1s8g1.jpg (GRAPHIC) — 97KB
- g905375ex99_1s9g1.jpg (GRAPHIC) — 112KB
- 0001193125-25-004428.txt ( ) — 2730KB
- lyra-20250110.xsd (EX-101.SCH) — 3KB
- lyra-20250110_lab.xml (EX-101.LAB) — 18KB
- lyra-20250110_pre.xml (EX-101.PRE) — 11KB
- d905375d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lyra Therapeutics, Inc. Date: January 10, 2025 By: /s/ Jason Cavalier Jason Cavalier, Chief Financial Officer